SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer

Robles-Zurita, J; Boyd, KA; Briggs, AH; Iveson, T; Kerr, RS; Saunders, MP; Cassidy, J; ... Paul, J; + view all Robles-Zurita, J; Boyd, KA; Briggs, AH; Iveson, T; Kerr, RS; Saunders, MP; Cassidy, J; Hollander, NH; Tabernero, J; Segelov, E; Glimelius, B; Harkin, A; Allan, K; McQueen, J; Pearson, S; Waterston, A; Medley, L; Wilson, C; Ellis, R; Essapen, S; Dhadda, AS; Hughes, R; Falk, S; Raouf, S; Rees, C; Olesen, RK; Propper, D; Bridgewater, J; Azzabi, A; Farrugia, D; Webb, A; Cunningham, D; Hickish, T; Weaver, A; Gollins, S; Wasan, HS; Paul, J; - view fewer (2018) SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer 10.1038/s41416-018-0319-z . (In press). Green open access

https://ift.tt/2P7sNjC